Abstract
Inhaled corticosteroid therapy (ICT) has a long and for the most part honourable history in the management of asthma. Introduced in an attempt to minimise the side effects associated with systemic treatment, early trials with nebulised hydrocortisone showed little if any added benefit,1 but with the introduction of beclomethasone dipropionate,2 ICT rapidly assumed a central rôle in the management of asthma, transforming the lives of millions of sufferers.

This publication has 0 references indexed in Scilit: